Literature DB >> 22748809

Clinical aspects of phage therapy.

Ryszard Międzybrodzki1, Jan Borysowski, Beata Weber-Dąbrowska, Wojciech Fortuna, Sławomir Letkiewicz, Krzysztof Szufnarowski, Zdzisław Pawełczyk, Paweł Rogóż, Marlena Kłak, Elżbieta Wojtasik, Andrzej Górski.   

Abstract

Phage therapy (PT) is a unique method of treatment of bacterial infections using bacteriophages (phages)-viruses that specifically kill bacteria, including their antibiotic-resistant strains. Over the last decade a marked increase in interest in the therapeutic use of phages has been observed, which has resulted from a substantial rise in the prevalence of antibiotic resistance of bacteria, coupled with an inadequate number of new antibiotics. The first, and so far the only, center of PT in the European Union is the Phage Therapy Unit (PTU) established at the Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wrocław, Poland in 2005. This center continues the rich tradition of PT in Poland, which dates from the early 1920s. The main objective of this chapter is to present a detailed retrospective analysis of the results of PT of 153 patients with a wide range of infections resistant to antibiotic therapy admitted for treatment at the PTU between January 2008 and December 2010. Analysis includes the evaluation of both the efficacy and the safety of PT. In general, data suggest that PT can provide good clinical results in a significant cohort of patients with otherwise untreatable chronic bacterial infections and is essentially well tolerated. In addition, the whole complex procedure employed to obtain and characterize therapeutic phage preparations, as well as ethical aspects of PT, is discussed.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22748809     DOI: 10.1016/B978-0-12-394438-2.00003-7

Source DB:  PubMed          Journal:  Adv Virus Res        ISSN: 0065-3527            Impact factor:   9.937


  108 in total

1.  Two Phages, phiIPLA-RODI and phiIPLA-C1C, Lyse Mono- and Dual-Species Staphylococcal Biofilms.

Authors:  Diana Gutiérrez; Dieter Vandenheuvel; Beatriz Martínez; Ana Rodríguez; Rob Lavigne; Pilar García
Journal:  Appl Environ Microbiol       Date:  2015-03-06       Impact factor: 4.792

Review 2.  Phage therapy as strategy to face post-antibiotic era: a guide to beginners and experts.

Authors:  Sabrina Royer; Aléxia Pinheiro Morais; Deivid William da Fonseca Batistão
Journal:  Arch Microbiol       Date:  2021-01-20       Impact factor: 2.552

3.  Immunogenicity studies of proteins forming the T4 phage head surface.

Authors:  Krystyna Dąbrowska; Paulina Miernikiewicz; Agnieszka Piotrowicz; Katarzyna Hodyra; Barbara Owczarek; Dorota Lecion; Zuzanna Kaźmierczak; Andrey Letarov; Andrzej Górski
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

Review 4.  Genetically Engineered Phages: a Review of Advances over the Last Decade.

Authors:  Diana P Pires; Sara Cleto; Sanna Sillankorva; Joana Azeredo; Timothy K Lu
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-01       Impact factor: 11.056

5.  Phage Therapy of Pneumonia Is Not Associated with an Overstimulation of the Inflammatory Response Compared to Antibiotic Treatment in Mice.

Authors:  Nicolas Dufour; Raphaëlle Delattre; Anne Chevallereau; Jean-Damien Ricard; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 6.  Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.

Authors:  Krystyna Dąbrowska; Stephen T Abedon
Journal:  Microbiol Mol Biol Rev       Date:  2019-10-30       Impact factor: 11.056

7.  Nonconventional Therapeutics against Staphylococcus aureus.

Authors:  Caroline M Grunenwald; Monique R Bennett; Eric P Skaar
Journal:  Microbiol Spectr       Date:  2018-11

8.  Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections.

Authors:  Marine Henry; Rob Lavigne; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

9.  Phage neutralization by sera of patients receiving phage therapy.

Authors:  Marzanna Łusiak-Szelachowska; Maciej Zaczek; Beata Weber-Dąbrowska; Ryszard Międzybrodzki; Marlena Kłak; Wojciech Fortuna; Sławomir Letkiewicz; Paweł Rogóż; Krzysztof Szufnarowski; Ewa Jończyk-Matysiak; Barbara Owczarek; Andrzej Górski
Journal:  Viral Immunol       Date:  2014-06-03       Impact factor: 2.257

10.  Engineering Phage Host-Range and Suppressing Bacterial Resistance through Phage Tail Fiber Mutagenesis.

Authors:  Kevin Yehl; Sébastien Lemire; Andrew C Yang; Hiroki Ando; Mark Mimee; Marcelo Der Torossian Torres; Cesar de la Fuente-Nunez; Timothy K Lu
Journal:  Cell       Date:  2019-10-03       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.